Alvotech

company

About

Alvotech specializes in making biosimilars to create biologic medicines.

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$70M
Industries
Biotechnology,Life Science,Pharmaceutical
Founded date
Jan 1, 2013
Number Of Employee
501 - 1000
Operating Status
Active
Stock Symbol
nasdaq:ALVO
Legal Name
ALVOTECH ehf.
Also Known As
Alvotech Biosimilars

Alvotech is a fully integrated specialty biopharmaceutical company focused exclusively on the development and manufacture of high-quality biosimilar medicines.

The company's goal is to improve patients' health and quality of life around the world by increasing access to effective therapies for various ailments.

Alvotech was established on January 1, 2013 by Róbert Wessman in Reykjavík, Gullbringusysla.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
7
$657M
Alvotech has raised a total of $657M in funding over 2 rounds. Their latest funding was raised on Jan 23, 2023 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 23, 2023 Post-IPO Equity $137M Detail
Dec 16, 2022 Post-IPO Debt $70M Detail
Jun 16, 2022 IPO Detail
Mar 15, 2021 Series Unknown $35M Detail
Oct 27, 2020 Series Unknown $65M 5 Detail

Investors

Number of Lead Investors
Number of Investors
1
6
Alvotech is funded by 6 investors. Fuji Pharma and Alvogen are the most recent investors.
Investor Name Lead Investor Funding Round
Fuji Pharma Yes Corporate Round
Alvogen Series Unknown
Athos Capital Series Unknown
Aztiq Pharma Series Unknown
Baxter Ventures Series Unknown
Shinhan Capital Series Unknown

Employee Profiles

Number of Employee Profiles
13
Alvotech has 13 current employee profiles, including Executive Róbert Wessman
Executive
Executive
Executive
Executive
Executive

Acquisition

Alvotech has acquired 1 organizations. Their most recent acquisition was Baliopharm on May 19, 2016. They acquired Baliopharm for 0.

Date Company Name
Industry Acquisition Type Price
May 19, 2016 Baliopharm
Biotechnology acquisition Detail